[Federal Register Volume 81, Number 109 (Tuesday, June 7, 2016)]
[Rules and Regulations]
[Pages 36458-36463]
[FR Doc No: 2016-13271]

-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Bureau of Industry and Security

15 CFR Parts 710, 745, and 774

[Docket No. 160302176-6176-01]
RIN 0694-AG88

Implementation of the February 2015 Australia Group (AG)
Intersessional Decisions and the June 2015 AG Plenary Understandings

AGENCY: Bureau of Industry and Security, Commerce.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Bureau of Industry and Security (BIS) publishes this final
rule to amend the Export Administration Regulations (EAR) to implement
the recommendations presented at the February 2015 Australia Group (AG)
intersessional implementation meeting, and later adopted pursuant to
the AG silent approval procedure, and the understandings reached at the
June 2015 AG Plenary meeting. This rule amends three Commerce Control
List (CCL) entries to reflect the February 2015 intersessional
recommendations that were adopted by the AG. Specifically, this rule
amends the CCL entry that controls chemical precursors by adding the
chemical diethylamine (C.A.S. 109-89-7), which was not previously
identified on the AG's ``Chemical Weapons Precursors'' common control
list. This rule also amends the CCL entry that controls certain human
and zoonotic pathogens and toxins by adding two viruses that were not
previously identified on the AG ``List of Human and Animal Pathogens
and Toxins for Export Control'' and by updating the nomenclature of
certain viruses that were already identified on this AG common control
list. In addition, this rule amends the CCL entry that controls
equipment capable of handling biological materials to reflect the AG
intersessional updates to the controls on biocontainment chambers,
isolators, and biological safety cabinets and the controls on aerosol
inhalation equipment described on the AG ``Control List of Dual-Use
Biological Equipment and Related Technology and Software.'' Consistent
with the understandings adopted at the June 2015 AG Plenary meeting,
this rule also amends the CCL entry that controls equipment capable of
handling biological materials by updating the controls on freeze-drying
(lyophilization) equipment.
    Finally, this rule amends the EAR to reflect the addition of Angola
and Burma as States Parties to the Chemical Weapons Convention (CWC)
and also amends the Chemical Weapons Convention Regulations (CWCR) to
reflect the addition of these two countries as States Parties.

DATES: This rule is effective June 7, 2016.

FOR FURTHER INFORMATION CONTACT: Richard P. Duncan, Ph.D., Director,
Chemical and Biological Controls Division, Office of Nonproliferation
and Treaty Compliance, Bureau of Industry and Security, Telephone:
(202) 482-3343, Email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: The Bureau of Industry and Security (BIS) is
amending the Export Administration Regulations (EAR) to implement the
recommendations presented at the Australia Group (AG) Intersessional
meeting held in The Hague, Netherlands, on February 4, 2015, and
adopted pursuant to the AG silent approval procedure in April 2015, and
the understandings reached at the AG Plenary meeting held in Perth,
Australia, from June 1-5, 2015. The AG is a multilateral forum
consisting of 41 participating countries that maintain export controls
on a list of chemicals, biological agents, and related equipment and
technology that could be used in a chemical or biological weapons
program. The AG periodically reviews items on its control list to
enhance the effectiveness of participating governments' national
controls and to achieve greater harmonization among these controls.

Amendments to the CCL Based on the February 2015 AG Intersessional
Recommendations

    This rule amends three Export Control Classification Numbers
(ECCNs) on the Commerce Control List (CCL) (see Supplement No. 1 to
part 774 of the EAR), as described below, to reflect the February 2015
intersessional recommendations that were adopted by the AG.

Amendments to ECCN 1C350 (Precursor Chemicals)

    This final rule amends ECCN 1C350 on the CCL, to reflect the
addition of the chemical diethylamine (C.A.S. 109-89-7) to the AG's
``Chemical Weapons Precursors'' common control list, by adding this
chemical to 1C350.d, which controls precursor chemicals identified on
the AG common control list that are not also ``scheduled'' chemicals
(i.e., chemicals identified as Schedule 1, Schedule 2, or Schedule 3
chemicals) under the Chemical Weapons Convention (CWC).
    Like the other precursor chemicals controlled under ECCN 1C350.d,
diethylamine requires a license for chemical/biological (CB) reasons to
destinations indicated under CB Column 2 on the Commerce Country Chart
(see Supplement No. 1 to part 738 of the EAR) and for anti-terrorism
(AT) reasons to destinations in Country Group E:1 (see Supplement No. 1
to part 742 of the EAR). Because none of the precursor chemicals
controlled under ECCN 1C350.d (including diethylamine) are identified
as ``scheduled'' chemicals under the CWC, these precursor chemicals do
not require a license for chemical weapons (CW) reasons. (See part 742
of the EAR for additional information on the AT controls that apply to
Iran, North Korea, Sudan, and Syria. See part 746 of the EAR for
additional information on the sanctions that apply to Iran, North
Korea, and Syria.)

Amendments to ECCN 1C351 (Human and Animal Pathogens and ``Toxins'')

    This final rule amends ECCN 1C351 on the CCL to reflect the
addition of two viruses (severe acute respiratory syndrome-related
coronavirus, a.k.a. SARS-related coronavirus, and reconstructed 1918
influenza virus) that were not previously identified on the AG ``List
of Human and Animal Pathogens and Toxins for Export Control'' and to
update the nomenclature for seventeen viruses that were already
identified on this AG common control list and in ECCN 1C351.a (nineteen
viruses were updated on the AG common control list, but only seventeen
viruses in ECCN 1C351.a required updating). Prior to the publication of
this final rule, the two viruses that are being added to ECCN 1C351.a
were listed under ECCN 1C351.b, which controls viruses identified on
the ``select agents'' lists maintained by the Animal and Plant Health
Inspection Service (APHIS), U.S. Department of Agriculture, and the
Centers for Disease Control and Prevention (CDC), U.S. Department of
Health and Human Services, but not identified on the AG ``List of Human
and Animal Pathogens and Toxins for Export Control.''
    The license requirements applicable to the viruses affected by the
amendments in this final rule (including the two viruses that are being
moved

from 1C351.b to 1C351.a) remain unchanged. Specifically, all of these
viruses continue to require a license for CB reasons to destinations
indicated under CB Column 1 on the Commerce Country Chart and for AT
reasons to destinations indicated in AT Column 1 on the Commerce
Country Chart.
    This final rule also makes conforming changes to ECCN 1C351 by
renumbering certain items in ECCN 1C351.a to reflect the addition of
the two aforementioned viruses (i.e., the SARS-related coronavirus and
the reconstructed 1918 influenza virus) and the updates to the
nomenclature for seventeen other viruses listed in 1C351.a. The
following table lists the viruses that are controlled under ECCN
1C351.a, as a result of the amendments made by this final rule, and
indicates the previous and current names and CCL designations for each
of these viruses. The names and CCL designations of thirteen viruses
were not affected by this rule (these viruses continue to be designated
as 1C351.a.1 through .a.8 and 1C351.a.42 through .a.46, as indicated in
the following table). Twenty-six additional viruses in 1C351.a, whose
names are not updated by this rule, have new CCL designations. All
seventeen of the viruses in 1C351.a whose names are updated by this
final rule also have new CCL designations, as do the two aforementioned
viruses that are being moved from 1C351.b to 1C351.a (both of whose
names are updated, as well).

----------------------------------------------------------------------------------------------------------------
  Previous names of AG-controlled     Current names of AG-controlled        Previous CCL         Current CCL
              viruses                             viruses                   designation          designation
----------------------------------------------------------------------------------------------------------------
African horse sickness virus......  No change.........................  ECCN 1C351.a.1.....  No change.
African swine fever virus.........  No change.........................  ECCN 1C351.a.2.....  No change.
Andes virus.......................  No change.........................  ECCN 1C351.a.3.....  No change.
Avian influenza virus.............  No change.........................  ECCN 1C351.a.4.....  No change.
Bluetongue virus..................  No change.........................  ECCN 1C351.a.5.....  No change.
Chapare virus.....................  No change.........................  ECCN 1C351.a.6.....  No change.
Chikungunya virus.................  No change.........................  ECCN 1C351.a.7.....  No change.
Choclo virus......................  No change.........................  ECCN 1C351.a.8.....  No change.
Congo-Crimean haemorrhagic fever    Crimean-Congo hemorrhagic fever     ECCN 1C351.a.9.....  ECCN 1C351.a.10.
 virus.                              virus.
Dengue fever virus................  Dengue virus......................  ECCN 1C351.a.10....  ECCN 1C351.a.11.
Dobrava-Belgrade virus............  No change.........................  ECCN 1C351.a.11....  ECCN 1C351.a.12.
Eastern equine encephalitis virus.  No change.........................  ECCN 1C351.a.12....  ECCN 1C351.a.13.
Ebola virus.......................  Ebolavirus (includes all members    ECCN 1C351.a.13....  ECCN 1C351.a.14.
                                     of the Ebolavirus genus).
Foot and mouth disease virus......  Foot-and-mouth disease virus......  ECCN 1C351.a.14....  ECCN 1C351.a.15.
Goat pox virus....................  Goatpox virus.....................  ECCN 1C351.a.15....  ECCN 1C351.a.16.
Guanarito virus...................  No change.........................  ECCN 1C351.a.16....  ECCN 1C351.a.17.
Hantaan virus.....................  No change.........................  ECCN 1C351.a.17....  ECCN 1C351.a.18.
Hendra virus (Equine                No change.........................  ECCN 1C351.a.18....  ECCN 1C351.a.19.
 morbillivirus).
Herpes virus (Aujeszky's disease).  Suid herpesvirus 1 (Pseudorabies    ECCN 1C351.a.19....  ECCN 1C351.a.51.
                                     virus; Aujeszky's disease).
Hog cholera virus (syn.: swine      Classical swine fever virus (Hog    ECCN 1C351.a.20....  ECCN 1C351.a.9.
 fever virus).                       cholera virus).
Japanese encephalitis virus.......  No change.........................  ECCN 1C351.a.21....  ECCN 1C351.a.20.
Junin virus.......................  No change.........................  ECCN 1C351.a.22....  ECCN 1C351.a.21.
Kyasanur Forest virus.............  Kyasanur Forest disease virus.....  ECCN 1C351.a.23....  ECCN 1C351.a.22.
Laguna Negra virus................  No change.........................  ECCN 1C351.a.24....  ECCN 1C351.a.23.
Lassa fever virus.................  Lassa virus.......................  ECCN 1C351.a.25....  ECCN 1C351.a.24.
Louping ill virus.................  No change.........................  ECCN 1C351.a.26....  ECCN 1C351.a.25.
Lujo virus........................  No change.........................  ECCN 1C351.a.27....  ECCN 1C351.a.26.
Lumpy skin disease virus..........  No change.........................  ECCN 1C352.a.28....  ECCN 1C351.a.27.
Lymphocytic choriomeningitis virus  No change.........................  ECCN 1C351.a.29....  ECCN 1C351.a.28.
Machupo virus.....................  No change.........................  ECCN 1C351.a.30....  ECCN 1C351.a.29.
Marburg virus.....................  Marburgvirus (includes all members  ECCN 1C351.a.31....  ECCN 1C351.a.30.
                                     of the Marburgvirus genus).
Monkey pox virus..................  Monkeypox virus...................  ECCN 1C351.a.32....  ECCN 1C351.a.31.
Murray Valley encephalitis virus..  No change.........................  ECCN 1C351.a.33....  ECCN 1C351.a.32.
Newcastle disease virus...........  No change.........................  ECCN 1C351.a.34....  ECCN 1C351.a.33.
Nipah virus.......................  No change.........................  ECCN 1C351.a.35....  ECCN 1C351.a.34.
Omsk haemorrhagic fever virus.....  Omsk hemorrhagic fever virus......  ECCN 1C351.a.36....  ECCN 1C351.a.35.
Oropouche virus...................  No change.........................  ECCN 1C351.a.37....  ECCN 1C351.a.36.
Peste des petits ruminants virus..  Peste-des-petits ruminants virus..  ECCN 1C351.a.38....  ECCN 1C351.a.37.
Porcine enterovirus type 9 (syn.:   Swine vesicular disease virus.....  ECCN 1C351.a.39....  ECCN 1C351.a.52.
 swine vesicular disease virus).
Powassan virus....................  No change.........................  ECCN 1C351.a.40....  ECCN 1C351.a.39.
Rabies virus and other members of   No change.........................  ECCN 1C351.a.41....  ECCN 1C351.a.40.
 the Lyssavirus genus.
Reconstructed replication           Reconstructed 1918 influenza virus  ECCN 1C351.b.1.....  ECCN 1C351.a.41.
 competent forms of the 1918
 pandemic influenza virus.
Rift Valley fever virus...........  No change.........................  ECCN 1C351.a.42....  No change.
Rinderpest virus..................  No change.........................  ECCN 1C351.a.43....  No change.
Rocio virus.......................  No change.........................  ECCN 1C351.a.44....  No change.
Sabia virus.......................  No change.........................  ECCN 1C351.a.45....  No change.
SARS-associated coronavirus (SARS-  Severe acute respiratory syndrome-  ECCN 1C351.b.2.....  ECCN 1C351.a.47.
 CoV).                               related coronavirus (SARS-related
                                     coronavirus).
Seoul virus.......................  No change.........................  ECCN 1C351.a.46....  No change.
Sheep pox virus...................  Sheeppox virus....................  ECCN 1C351.a.47....  ECCN 1C351.a.48.
Sin nombre virus..................  Sin Nombre virus..................  ECCN 1C351.a.48....  ECCN 1C351.a.49.

St. Louis encephalitis virus......  No change (correction needed on AG  ECCN 1C351.a.49....  ECCN 1C351.a.50.
                                     common control list, only).
Teschen disease virus.............  Porcine Teschovirus...............  ECCN 1C351.a.50....  ECCN 1C351.a.38.
Tick-borne encephalitis virus       No change (correction needed on AG  ECCN 1C351.a.51....  ECCN 1C351.a.53.
 (Russian Spring-Summer              common control list, only).
 encephalitis virus).
Variola virus.....................  No change.........................  ECCN 1C351.a.52....  ECCN 1C351.a.54.
Venezuelan equine encephalitis      No change.........................  ECCN 1C351.a.53....  ECCN 1C351.a.55.
 virus.
Vesicular stomatitis virus........  No change.........................  ECCN 1C351.a.54....  ECCN 1C351.a.56.
Western equine encephalitis virus.  No change.........................  ECCN 1C351.a.55....  ECCN 1C351.a.57.
Yellow fever virus................  No change.........................  ECCN 1C351.a.56....  ECCN 1C351.a.58.
----------------------------------------------------------------------------------------------------------------

    With the transfer of two viruses (i.e., severe acute respiratory
syndrome-related coronavirus, a.k.a. SARS-related coronavirus, and
reconstructed 1918 influenza virus) from ECCN 1C351.b to 1C351.a by
this rule, only one virus continues to be controlled under 1C351.b:
Tick-borne encephalitis virus (Siberian subtype, formerly West Siberian
virus), which is listed in 1C351.b.3. This rule makes a conforming
change to ECCN 1C351.b.3 by updating the cross reference therein to
tick-borne encephalitis virus (Far Eastern subtype, formerly known as
Russian Spring-Summer encephalitis virus) to reflect the re-designation
of that virus (now listed under ECCN 1C351.a.53) by the amendments to
ECCN 1C351.a described above.

Amendments to ECCN 2B352 (Equipment Capable of Use in Handling
Biological Materials)

    This final rule amends ECCN 2B352 on the CCL to reflect changes to
the AG ``Control List of Dual-Use Biological Equipment and Related
Technology and Software'' based on the February 2015 intersessional
recommendations that were adopted by the AG. Specifically, this rule
amends the controls on biocontainment chambers, isolators, and
biological safety cabinets described in 2B352.g.2 to more fully
identify the characteristics that such equipment must possess in order
to be controlled under ECCN 2B352. As amended by this rule, ECCN
2B352.g.2 controls biocontainment chambers, isolators, or biological
safety cabinets having all of the following characteristics, for normal
operation: (i) A fully enclosed workspace where the operator is
separated from the work by a physical barrier; (ii) the ability to
operate at negative pressure; (iii) the means to safely manipulate
items in the workspace; and (iv) the supply and exhaust air to and from
the workspace is high-efficiency particulate air (HEPA) filtered.
    Consistent with the AG intersessional changes described above, this
rule also adds two notes to ECCN 2B352 to further clarify the scope of
the controls in 2B352.g.2. Note 1 to ECCN 2B352.g.2 indicates that the
items subject to these controls include class III biosafety cabinets,
as specified in the World Health Organization (WHO) Laboratory
Biosafety Manual (3rd edition, Geneva, 2004) or constructed in
accordance with national standards, regulations or guidance. Note 2 to
ECCN 2B352.g.2 indicates that these controls do not apply to isolators
specially designed for barrier nursing or transportation of infected
patients.
    This rule also amends the controls on aerosol inhalation equipment
described in ECCN 2B352.h to include nose-only exposure apparatus. As
amended by this final rule, ECCN 2B352.h now controls the following
aerosol inhalation equipment designed for aerosol challenge testing
with microorganisms, viruses or toxins: (i) Whole-body exposure
chambers having a capacity of 1 cubic meter or greater; and (ii) nose-
only exposure apparatus utilizing directed aerosol flow and having a
capacity for the exposure of 12 or more rodents, or 2 or more animals
other than rodents, and closed animal restraint tubes designed for use
with such apparatus.
    All items controlled under ECCN 2B352 require a license for CB
reasons to destinations indicated under CB Column 2 on the Commerce
Country Chart and for AT reasons to destinations indicated in AT Column
1 on the Commerce Country Chart.

Amendments to the CCL Based on the June 2015 AG Plenary Understandings

Amendments to ECCN 2B352 (Equipment Capable of Use in Handling
Biological Materials)

    This final rule also amends ECCN 2B352 on the CCL to reflect
changes to the AG ``Control List of Dual-Use Biological Equipment and
Related Technology and Software'' based on the understandings reached
at the June 2015 AG Plenary meeting. Specifically, this rule amends
2B352.e to control steam, gas or vapor sterilizable freeze-drying
equipment with a condenser capacity of 10 kg of ice or greater in 24
hours (10 liters of water or greater in 24 hours) and less than 1000 kg
of ice in 24 hours (less than 1,000 liters of water in 24 hours). This
change is being made in recognition of the increasing viability of gas
or vapor sterilizable freeze-drying equipment as an efficient and low-
cost alternative to steam sterilization.

Conforming Change to ECCN 1C351 (Human and Animal Pathogens and
``Toxins'')

    In addition to the AG plenary and intersessional changes described
above, this rule amends ECCN 1C351 by adding a fifth note to the
License Requirement Notes in the License Requirements section of this
ECCN. This new License Requirement Note is intended to provide
guidance, consistent with the AG ``List of Human and Animal Pathogens
and Toxins for Export Control,'' in determining whether a particular
pathogen or ``toxin'' is controlled under ECCN 1C351. License
Requirement Note 5 reads as follows:

    Biological agents and pathogens are controlled under ECCN 1C351
when they are an isolated live culture of a pathogen agent, or a
preparation of a toxin agent that has been isolated or extracted
from any source or material, including living material that has been
deliberately inoculated or contaminated with the agent. Isolated
live cultures of a pathogen agent include live cultures in dormant
form or in dried preparations, whether the agent is natural,
enhanced or modified.

Addition of Angola and Burma as States Parties to the Chemical Weapons
Convention (CWC)

    This rule also amends the EAR to reflect the addition of Angola and
Burma as States Parties to the CWC on October 16, 2015, and August 7,
2015, respectively. Specifically, this rule amends Supplement No. 2 to
part 745 of the EAR (States Parties to the CWC) to add Angola and Burma
in alphabetical order. Because Angola and Burma are not AG
participating

countries, their addition to the list of CWC States Parties in
Supplement No. 2 to part 745 does not affect the CB Column 1 and CB
Column 2 license requirements for these countries that are indicated in
Supplement No. 1 to part 738 of the EAR (Commerce Country Chart). The
CB Column 3 license requirements indicated for Burma, in the Commerce
Country Chart, also continue to apply. However, a license is no longer
required for CB or CW reasons for exports to Angola or Burma of
mixtures and test kits controlled under ECCN 1C395.a and .b,
respectively, although a license would be required if any of the end-
user or end-use requirements in part 744 of the EAR apply.
    In order to maintain consistency between the EAR and the Chemical
Weapons Convention Regulations (CWCR) (15 CFR parts 710-721), with
respect to those countries that are identified as States Parties to the
CWC, this rule also amends Supplement No. 1 to part 710 of the CWCR
(States Parties to the CWC) to add Angola and Burma in alphabetical
order.

Effect of This Rule on the Scope of the CB Controls in the EAR

    The changes made by this rule only marginally affect the scope of
the EAR controls on precursor chemicals, human and animal pathogens/
toxins, and equipment capable of use in handling biological materials.
    The amendments to ECCN 1C350, which add the chemical diethylamine
(C.A.S. 109-89-7), are expected to have only a small impact on the
scope of the CB controls in this ECCN. This chemical has corrosive
properties that, in combination with its flammable characteristics,
cause it to be categorized as a hazardous substance. As such, this
chemical is regulated by the Occupational Safety and Health
Administration (OSHA), the Drug Enforcement Administration (DEA), and
the Environmental Protection Agency (EPA) and also is listed in the
Department of Transportation's (DOT) Hazardous Materials Table (see 49
CFR 171.101). For these reasons, together with the limited number of
commercial applications for this chemical, there is a relatively low
volume of exports of this chemical from the United States. Therefore,
the addition of this chemical to ECCN 1C350 is not expected to have a
significant impact on the number of export license applications that
must be submitted to BIS for items controlled under this ECCN.
    The scope of the CCL-based CB controls on human and animal
pathogens and toxins was not affected by the addition of two viruses
(i.e., severe acute respiratory syndrome-related coronavirus, a.k.a.
SARS-related coronavirus, and reconstructed 1918 influenza virus) to
ECCN 1C351.a because these viruses were controlled under ECCN 1C351.b
prior to the publication of this rule, and the license requirements
that apply to items listed under 1C351.a are identical to those that
apply to items listed under 1C351.b. Therefore, these changes are not
expected to have a significant impact on the number of license
applications that will have to be submitted for such items.
    The addition of new License Requirement Note 5 to ECCN 1C351 is
merely intended to provide guidance, consistent with the AG ``List of
Human and Animal Pathogens and Toxins for Export Control,'' for
determining whether a particular pathogen or ``toxin'' is controlled
under this ECCN. It does not affect the scope of the controls of this
ECCN and, therefore, is not expected to have any discernable effect on
the number of license applications that will have to be submitted for
items controlled under ECCN 1C351.
    Although the updates in this rule to the controls on freeze-drying
(lyophilization) equipment (see ECCN 2B352.e), biocontainment chambers,
isolators, and biological safety cabinets (see ECCN 2B352.g.2) and
aerosol inhalation equipment (see ECCN 2B352.h) represent an expansion
in the number of items that require a license under ECCN 2B352, the
expanded controls apply to only a relatively small percentage of these
types of items that were not controlled under ECCN 2B352 prior to the
publication of this rule. Consequently, any increase in the number of
license applications resulting from this change is not expected to be
significant, when considered as a percentage of these types of items.
    Finally, the amendments adding Angola and Burma to Supplement No. 2
to part 745 of the EAR (States Parties to the CWC) and Supplement No. 1
to part 710 of the CWCR are expected to have only a small impact on the
scope of the controls applicable to exports to these countries of items
on the CCL that are also identified on the AG common control lists.
Because Angola and Burma are not AG participating countries, the CB
Column 1 and CB Column 2 license requirements for these countries, as
indicated in Supplement No. 1 to part 738 of the EAR (Commerce Country
Chart), continue to apply. In addition, the CB Column 3 license
requirements indicated for Burma, in the Commerce Country Chart,
continue to apply. However, under ECCN 1C395, a license is no longer
required for CB or CW reasons for exports to Angola or Burma of
mixtures and test kits controlled by ECCN 1C395.a and .b, respectively.
Therefore, collectively, these changes are expected to result in a
small decrease in the number of license applications that will have to
be submitted for these two countries.
    Although the Export Administration Act expired on August 20, 2001,
the President, through Executive Order 13222 of August 17, 2001, 3 CFR,
2001 Comp., p. 783 (2002), as amended by Executive Order 13637 of March
8, 2013, 78 FR 16129 (March 13, 2013), and as extended by the Notice of
August 7, 2015 (80 FR 48233 (Aug. 11, 2015)), has continued the Export
Administration Regulations in effect under the International Emergency
Economic Powers Act (50 U.S.C. 1701 et seq.). BIS continues to carry
out the provisions of the Export Administration Act, as appropriate and
to the extent permitted by law, pursuant to Executive Order 13222 as
amended by Executive Order 13637.

Rulemaking Requirements

    1. Executive Orders 13563 and 12866 direct agencies to assess all
costs and benefits of available regulatory alternatives and, if
regulation is necessary, to select regulatory approaches that maximize
net benefits (including potential economic, environmental, public
health and safety effects, distributive impacts, and equity). Executive
Order 13563 emphasizes the importance of quantifying both costs and
benefits, of reducing costs, of harmonizing rules, and of promoting
flexibility. This rule has been designated a ``significant regulatory
action,'' although not economically significant, under section 3(f) of
Executive Order 12866. Accordingly, the rule has been reviewed by the
Office of Management and Budget.
    2. Notwithstanding any other provision of law, no person is
required to respond to, nor shall any person be subject to a penalty
for failure to comply with, a collection of information subject to the
requirements of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et
seq.) (PRA), unless that collection of information displays a currently
valid Office of Management and Budget (OMB) Control Number. This rule
contains a collection of information subject to the requirements of the
PRA. This collection has been approved by OMB under Control Number
0694-0088 (Multi-Purpose Application), which carries a burden hour
estimate of 58

minutes to prepare and submit form BIS-748. Send comments regarding
this burden estimate or any other aspect of this collection of
information, including suggestions for reducing the burden, to Jasmeet
Seehra, Office of Management and Budget, by email to
<EMAIL_ADDRESS>or by fax to<PHONE_NUMBER>; and to the
Regulatory Policy Division, Bureau of Industry and Security, Department
of Commerce, 14th Street & Pennsylvania Avenue NW., Room 2705,
Washington, DC 20230 or by email to<EMAIL_ADDRESS>    3. This rule does not contain policies with Federalism implications
as that term is defined in Executive Order 13132.
    4. The provisions of the Administrative Procedure Act (5 U.S.C.
553) requiring notice of proposed rulemaking, the opportunity for
public participation, and a delay in effective date, are inapplicable
because this regulation involves a military and foreign affairs
function of the United States (see 5 U.S.C. 553(a)(1)). Immediate
implementation of these amendments is non-discretionary and fulfills
the United States' international obligation to the Australia Group
(AG). The AG contributes to international security and regional
stability through the harmonization of export controls and seeks to
ensure that exports do not contribute to the development of chemical
and biological weapons. The AG consists of 41 member countries that act
on a consensus basis and the amendments set forth in this rule
implement changes made to the AG common control lists (as a result of
the adoption of the recommendations made at the February 2015 AG
intersessional meeting and the understandings reached at the June 2015
AG plenary meeting) and other changes that are necessary to ensure
consistency with the controls maintained by the AG. Because the United
States is a significant exporter of the items in this rule, immediate
implementation of this provision is necessary for the AG to achieve its
purpose. Any delay in implementation will create a disruption in the
movement of affected items globally because of disharmony between
export control measures implemented by AG members, resulting in tension
between member countries. Export controls work best when all countries
implement the same export controls in a timely manner.
    Further, no other law requires that a notice of proposed rulemaking
and an opportunity for public comment be given for this final rule.
Because a notice of proposed rulemaking and an opportunity for public
comment are not required to be given for this rule under the
Administrative Procedure Act or by any other law, the analytical
requirements of the Regulatory Flexibility Act (5 U.S.C. 601 et seq.)
are not applicable. Therefore, this regulation is issued in final form.

List of Subjects

15 CFR Part 710

    Chemicals, Exports, Foreign trade, Imports, Treaties.

15 CFR Part 745

    Administrative practice and procedure, Chemicals, Exports, Foreign
trade, Reporting and recordkeeping requirements.

15 CFR Part 774

    Exports, Reporting and recordkeeping requirements.

    For the reasons stated in the preamble, part 710 of the Chemical
Weapons Convention Regulations (15 CFR parts 710-721) and parts 745 and
774 of the Export Administration Regulations (15 CFR parts 730-774) are
amended as follows:

PART 710--[AMENDED]

0
1. The authority citation for Part 710 continues to read as follows:

    Authority:  22 U.S.C. 6701 et seq.; E.O. 13128, 64 FR 36703, 3
CFR 1999 Comp., p. 199.

0
2. Supplement No. 1 to Part 710 is amended by revising the undesignated
center heading ``List of States Parties as of November 1, 2013'' to
read ``List of States Parties as of June 1, 2016'' and by adding, in
alphabetical order, the countries ``Angola'' and ``Burma''.

PART 745--[AMENDED]

0
3. The authority citation for Part 745 continues to read as follows:

    Authority:  50 U.S.C. 1701 et seq.; E.O. 12938, 59 FR 59099, 3
CFR, 1994 Comp., p. 950); Notice of November 12, 2015, 80 FR 70667
(November 13, 2015).

0
4. Supplement No. 2 to Part 745 is amended by revising the undesignated
center heading ``List of States Parties as of November 1, 2013'' to
read ``List of States Parties as of June 1, 2016'' and by adding, in
alphabetical order, the countries ``Angola'' and ``Burma''.

PART 774--[AMENDED]

0
5. The authority citation for Part 774 continues to read as follows:

    Authority:  50 U.S.C. 4601 et seq.; 50 U.S.C. 1701 et seq.; 10
U.S.C. 7420; 10 U.S.C. 7430(e); 22 U.S.C. 287c, 22 U.S.C. 3201 et
seq.; 22 U.S.C. 6004; 30 U.S.C. 185(s), 185(u); 42 U.S.C. 2139a; 43
U.S.C. 1354; 15 U.S.C. 1824a; 50 U.S.C. 4305; 22 U.S.C. 7201 et
seq.; 22 U.S.C. 7210; E.O. 13026, 61 FR 58767, 3 CFR, 1996 Comp., p.
228; E.O. 13222, 66 FR 44025, 3 CFR, 2001 Comp., p. 783; Notice of
August 7, 2015, 80 FR 48233 (August 11, 2015).

0
6. In Supplement No. 1 to Part 774, Category 1--Special Materials and
Related Equipment, Chemicals, ``Microorganisms'' and ``Toxins,'' ECCN
1C350 is amended by revising paragraph d.24 and adding a new paragraph
d.25 in the ``Items'' paragraph, under the ``List of Items Controlled''
section, to read as follows:

Supplement No. 1 to Part 774--The Commerce Control List

* * * * *
1C350 Chemicals that may be used as precursors for toxic chemical
agents (see List of Items Controlled).
* * * * *

List of Items Controlled

* * * * *
Items:
* * * * *
    d. * * *
    d.24. (C.A.S. #16893-85-9) Sodium hexafluorosilicate;
    d.25. (C.A.S. #109-89-7) Diethylamine.

0
7. In Supplement No. 1 to Part 774 (the Commerce Control List),
Category 1--Special Materials and Related Equipment, Chemicals,
``Microorganisms'' and ``Toxins,'' ECCN 1C351 is amended by adding a
Note 5 to the ``License Requirement Notes,'' under the ``License
Requirements'' section, and by revising paragraphs a. and b. in the
``Items'' paragraph, under the ``List of Items Controlled'' section, to
read as follows:

1C351 Human and animal pathogens and ``toxins'', as follows (see
List of Items Controlled).

License Requirements

* * * * *
License Requirement Notes: * * *

    5. Biological agents and pathogens are controlled under this
ECCN 1C351 when they are an isolated live culture of a pathogen
agent, or a preparation of a toxin agent that has been isolated or
extracted from any source or material, including living material
that has been deliberately inoculated or contaminated with the
agent. Isolated live cultures of a pathogen agent include live
cultures in dormant form or in dried preparations, whether the agent
is natural, enhanced or modified.

List of Items Controlled

* * * * *

Items:

    a. Viruses identified on the Australia Group (AG) ``List of
Human and Animal

Pathogens and Toxins for Export Control,'' as follows:
    a.1. African horse sickness virus;
    a.2. African swine fever virus;
    a.3. Andes virus;
    a.4. Avian influenza (AI) viruses identified as having high
pathogenicity (HP), as follows:
    a.4.a. AI viruses that have an intravenous pathogenicity index
(IVPI) in 6-week-old chickens greater than 1.2; or
    a.4.b. AI viruses that cause at least 75% mortality in 4- to 8-
week-old chickens infected intravenously.
    Note: Avian influenza (AI) viruses of the H5 or H7 subtype that
do not have either of the characteristics described in 1C352.a.4
(specifically, 1C352.a.4.a or a.4.b) should be sequenced to
determine whether multiple basic amino acids are present at the
cleavage site of the haemagglutinin molecule (HA0). If the amino
acid motif is similar to that observed for other HPAI isolates, then
the isolate being tested should be considered as HPAI and the virus
is controlled under 1C352.a.4.
    a.5. Bluetongue virus;
    a.6. Chapare virus;
    a.7. Chikungunya virus;
    a.8. Choclo virus;
    a.9. Classical swine fever virus (Hog cholera virus);
    a.10. Crimean-Congo hemorrhagic fever virus;
    a.11. Dengue virus;
    a.12. Dobrava-Belgrade virus;
    a.13. Eastern equine encephalitis virus;
    a.14. Ebolavirus (includes all members of the Ebolavirus genus);
    a.15. Foot-and-mouth disease virus;
    a.16. Goatpox virus;
    a.17. Guanarito virus;
    a.18. Hantaan virus;
    a.19. Hendra virus (Equine morbillivirus);
    a.20. Japanese encephalitis virus;
    a.21. Junin virus;
    a.22. Kyasanur Forest disease virus;
    a.23. Laguna Negra virus;
    a.24. Lassa virus;
    a.25. Louping ill virus;
    a.26. Lujo virus;
    a.27. Lumpy skin disease virus;
    a.28. Lymphocytic choriomeningitis virus;
    a.29. Machupo virus;
    a.30. Marburgvirus (includes all members of the Marburgvirus
genus);
    a.31. Monkeypox virus;
    a.32. Murray Valley encephalitis virus;
    a.33. Newcastle disease virus;
    a.34. Nipah virus;
    a.35. Omsk hemorrhagic fever virus;
    a.36. Oropouche virus;
    a.37. Peste-des-petits ruminants virus;
    a.38. Porcine Teschovirus;
    a.39. Powassan virus;
    a.40. Rabies virus and all other members of the Lyssavirus
genus;
    a.41. Reconstructed 1918 influenza virus;
    Technical Note: 1C351.a.41 includes reconstructed replication
competent forms of the 1918 pandemic influenza virus containing any
portion of the coding regions of all eight gene segments.
    a.42. Rift Valley fever virus;
    a.43. Rinderpest virus;
    a.44. Rocio virus;
    a.45. Sabia virus;
    a.46. Seoul virus;
    a.47. Severe acute respiratory syndrome-related coronavirus
(SARS-related coronavirus);
    a.48. Sheeppox virus;
    a.49. Sin Nombre virus;
    a.50. St. Louis encephalitis virus;
    a.51. Suid herpesvirus 1 (Pseudorabies virus; Aujeszky's
disease);
    a.52. Swine vesicular disease virus;
    a.53. Tick-borne encephalitis virus (Far Eastern subtype,
formerly known as Russian Spring-Summer encephalitis virus--see
1C351.b.3 for Siberian subtype);
    a.54. Variola virus;
    a.55. Venezuelan equine encephalitis virus;
    a.56. Vesicular stomatitis virus;
    a.57. Western equine encephalitis virus; or
    a.58. Yellow fever virus.
    b. Viruses identified on the APHIS/CDC ``select agents'' lists
(see Related Controls paragraph #2 for this ECCN), but not
identified on the Australia Group (AG) ``List of Human and Animal
Pathogens and Toxins for Export Control,'' as follows:
    b.1. [Reserved];
    b.2. [Reserved]; or
    b.3. Tick-borne encephalitis virus (Siberian subtype, formerly
West Siberian virus--see 1C351.a.53 for Far Eastern subtype).
* * * * *

0
8. In Supplement No. 1 to Part 774 (the Commerce Control List),
Category 2--Materials Processing, ECCN 2B352 is amended in the
``Items'' paragraph, under the List of Items Controlled section, by
revising paragraph e., by revising paragraph g.2., by adding Notes 1
and 2 to paragraph g.2., and by revising paragraph h., to read as
follows:

2B352 Equipment Capable of Use in Handling Biological Materials, as
Follows (See List of Items Controlled).

* * * * *

List of Items Controlled

* * * * *
Items:
* * * * *
    e. Steam, gas or vapor sterilizable freeze-drying equipment with
a condenser capacity of 10 kg of ice or greater in 24 hours (10
liters of water or greater in 24 hours) and less than 1000 kg of ice
in 24 hours (less than 1,000 liters of water in 24 hours).
* * * * *
    g. * * *
    g.2. Biocontainment chambers, isolators, or biological safety
cabinets having all of the following characteristics, for normal
operation:
    g.2.a. Fully enclosed workspace where the operator is separated
from the work by a physical barrier;
    g.2.b. Able to operate at negative pressure;
    g.2.c. Means to safely manipulate items in the workspace; and
    g.2.d. Supply and exhaust air to and from the workspace is high-
efficiency particulate air (HEPA) filtered.
    Note 1 to 2B352.g.2: 2B352.g.2 controls class III biosafety
cabinets, as specified in the WHO Laboratory Biosafety Manual (3rd
edition, Geneva, 2004) or constructed in accordance with national
standards, regulations or guidance.
    Note 2 to 2B352.g.2: 2B352.g.2 does not control isolators
``specially designed'' for barrier nursing or transportation of
infected patients.
    h. Aerosol inhalation equipment designed for aerosol challenge
testing with microorganisms, viruses or toxins, as follows:
    h.1. Whole-body exposure chambers having a capacity of 1 cubic
meter or greater.
    h.2. Nose-only exposure apparatus utilizing directed aerosol
flow and having a capacity for the exposure of 12 or more rodents,
or two or more animals other than rodents, and closed animal
restraint tubes designed for use with such apparatus.
* * * * *

    Dated: May 31, 2016.
Kevin J. Wolf,
Assistant Secretary for Export Administration.
[FR Doc. 2016-13271 Filed 6-6-16; 8:45 am]
 BILLING CODE 3510-33-P


[Federal Register Volume 80, Number 142 (Friday, July 24, 2015)]
[Proposed Rules]
[Pages 44013-44014]
[FR Doc No: 2015-17665]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[EPA-R01-OAR-2014-0842; A-1-FRL-9927-33-Region 1]

Approval and Promulgation of Air Quality Implementation Plans;
Connecticut; Prevention of Significant Deterioration and Nonattainment
New Source Review

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

-----------------------------------------------------------------------

SUMMARY: The Environmental Protection Agency (EPA) is proposing to
approve certain revisions to the State of Connecticut State
Implementation Plan (SIP) relating to regulation of fine particulate
matter (PM2.5) emissions within the context of EPA's
Prevention of Significant Deterioration (PSD) regulations. EPA is also
proposing to approve clarifications to the applicability section of
Connecticut's Nonattainment New Source Review (NNSR) regulations. These
revisions

will be part of Connecticut's major stationary source preconstruction
permitting programs, and are intended to align Connecticut's
regulations with the federal PSD and NNSR regulations. This action is
being taken in accordance with the Clean Air Act (CAA).

DATES: Written comments must be received on or before August 24, 2015.

ADDRESSES: Submit your comments, identified by Docket ID Number EPA-
R01-OAR-2014-0842 by one of the following methods:
    1. www.regulations.gov: Follow the on-line instructions for
submitting comments.
    2. Email<EMAIL_ADDRESS>    3. Fax:<PHONE_NUMBER>7.
    4. Mail: ``Docket Identification Number EPA-R01-OAR-2014-0842'',
Donald Dahl, U.S. Environmental Protection Agency, EPA New England
Regional Office, Office of Ecosystem Protection, Air Permits, Toxics,
and Indoor Programs Unit, 5 Post Office Square--Suite 100, (Mail code
OEP05-2), Boston, MA 02109-3912.
    5. Hand Delivery or Courier. Deliver your comments to: Donald Dahl,
U.S. Environmental Protection Agency, EPA New England Regional Office,
Office of Ecosystem Protection, Air Permits, Toxics, and Indoor
Programs Unit, 5 Post Office Square--Suite 100 (Mail code OEP05-2),
Boston, MA 02109-3912. Such deliveries are only accepted during the
Regional Office's normal hours of operation. The Regional Office's
official hours of business are Monday through Friday, 8:30 a.m. to 4:30
p.m., excluding legal holidays.
    Please see the direct final rule which is located in the Rules and
Regulations section of this issue of the Federal Register for detailed
instructions on how to submit comments.

FOR FURTHER INFORMATION CONTACT: Donald Dahl, U.S. Environmental
Protection Agency, EPA New England Regional Office, Office of Ecosystem
Protection, Air Permits, Toxics, and Indoor Programs Unit, 5 Post
Office Square--Suite 100, (mail code OEP05-2), Boston, MA 02109-3912.
Mr. Dahl's telephone number is<PHONE_NUMBER>; email address:
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: In the Rules and Regulations section of this
issue of the Federal Register, EPA is approving the State's SIP
submittal as a direct final rule without prior proposal because the
Agency views this as a noncontroversial submittal and anticipates no
adverse comments. A detailed rationale for the approval is set forth in
the direct final rule. If no adverse comments are received in response
to this action rule, no further activity is contemplated. If EPA
receives adverse comments, the direct final rule will be withdrawn and
all public comments received will be addressed in a subsequent final
rule based on this proposed rule. EPA will not institute a second
comment period. Any parties interested in commenting on this action
should do so at this time. Please note that if EPA receives adverse
comment on an amendment, paragraph, or section of this rule and if that
provision may be severed from the remainder of the rule, EPA may adopt
as final those provisions of the rule that are not the subject of an
adverse comment.
    For additional information, see the direct final rule which is
located in the Rules and Regulations section of this issue of the
Federal Register.

    Dated: April 20, 2015.
H. Curtis Spalding,
Regional Administrator, EPA New England.
[FR Doc. 2015-17665 Filed 7-23-15; 8:45 am]
BILLING CODE 6560-50-P


[Federal Register Volume 79, Number 82 (Tuesday, April 29, 2014)]
[Notices]
[Pages 24057-24058]
[FR Doc No: 2014-09624]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

Agency Information Collection Activities: Requests for Comments;
Clearance of Renewed Approval of Information Collection: Generic
Clearance for the Collection of Qualitative Feedback on Agency Service
Delivery

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice and request for comments.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, FAA
invites public comments about our intention to request the Office of
Management and Budget (OMB) approval to renew a generic information
collection. The Federal Register Notice with a 60-day comment period
soliciting comments on the following collection of information was
published on February 11, 2014, vol. 79, no. 28, pages 8232-8233. As
part of a Federal Government-wide effort to streamline the process to
seek feedback from the public on service delivery, FAA has an approved
Generic Information Collection Request (Generic ICR): ``Generic
Clearance for the Collection of Qualitative Feedback on Agency Service
Delivery''.

DATES: Written comments should be submitted by May 29, 2014.

FOR FURTHER INFORMATION CONTACT: Kathy DePaepe at<PHONE_NUMBER>, or by
email at<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:
    OMB Control Number: 2120-0746.
    Title: Generic Clearance for the Collection of Qualitative Feedback
on Agency Service Delivery.
    Form Numbers: There are no FAA forms associated with this generic
information collection.
    Type of Review: Renewal of a generic information collection.
    Background: The information collection activity will garner
qualitative customer and stakeholder feedback in an efficient, timely
manner, in accordance with the Administration's commitment to improving
service delivery. By qualitative feedback we mean information that
provides useful insights on perceptions and opinions, but are not
statistical surveys that yield quantitative results that can be
generalized to the population of study. This feedback will provide
insights into customer or stakeholder perceptions, experiences and
expectations, provide an early warning of issues with service, or focus
attention on areas where communication, training or changes in
operations might improve delivery of products or services. These
collections will allow for ongoing, collaborative and actionable
communications between the Agency and its customers and stakeholders.
It will also allow feedback to contribute directly to the improvement
of program management.
    Feedback collected under this generic clearance will provide useful
information, but it will not yield data that can be generalized to the
overall population. This type of generic clearance for qualitative
information will not be used for quantitative information collections
that are designed to yield reliably actionable results, such as
monitoring trends over time or documenting program performance. Such
data uses require more rigorous designs that address: the target
population to which generalizations will be made, the sampling frame,
the sample design (including stratification and clustering), the
precision requirements or power calculations that justify the proposed
sample size, the expected response rate, methods for assessing
potential non-response bias, the protocols for data

collection, and any testing procedures that were or will be undertaken
prior fielding the study. Depending on the degree of influence the
results are likely to have, such collections may still be eligible for
submission for other generic mechanisms that are designed to yield
quantitative results.
    Respondents: Approximately 2,813 Individuals and Households,
Businesses and Organizations, State, Local or Tribal Government.
    Frequency: Once per request.
    Estimated Average Burden per Response: 15 minutes.
    Estimated Total Annual Burden: 1,407 hours.
    Addresses:Interested persons are invited to submit written comments
on the proposed information collection to the Office of Information and
Regulatory Affairs, Office of Management and Budget. Comments should be
addressed to the attention of the Desk Officer, Department of
Transportation/FAA, and sent via electronic mail to<EMAIL_ADDRESS>or faxed to<PHONE_NUMBER>, or mailed to the
Office of Information and Regulatory Affairs, Office of Management and
Budget, Docket Library, Room 10102, 725 17th Street NW., Washington, DC
20503.
    Public Comments Invited: You are asked to comment on any aspect of
this information collection, including (a) Whether the proposed
collection of information is necessary for FAA's performance; (b) the
accuracy of the estimated burden; (c) ways for FAA to enhance the
quality, utility and clarity of the information collection; and (d)
ways that the burden could be minimized without reducing the quality of
the collected information. The agency will summarize and/or include
your comments in the request for OMB's clearance of this information
collection.

    Issued in Washington, DC on April 22, 2014.
Albert R. Spence,
FAA Assistant Information Collection Clearance Officer, IT Enterprises
Business Services Division, ASP-110.
[FR Doc. 2014-09624 Filed 4-28-14; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 83, Number 59 (Tuesday, March 27, 2018)]
[Rules and Regulations]
[Pages 13105-13106]
[FR Doc No: 2018-06065]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 5

[Docket No. FDA-2018-N-0011]

Revision of Organization; Technical Amendment

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is amending
its regulations to reflect organizational change for the Office of
Regulatory Policy, Center for Drug Evaluation and Research (CDER),
Office of Medical Products and Tobacco. FDA is taking this action to
ensure accuracy and clarity in the Agency's regulations.

DATES: This rule is effective March 27, 2018.

FOR FURTHER INFORMATION CONTACT: Florine Purdie, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave. Bldg. 51, Rm. 6248, Silver Spring, MD 20993-0002, 301-
796-3601.

SUPPLEMENTARY INFORMATION: FDA is amending 21 CFR 5.1100 to update the
organizational information for the Office of Regulatory Policy, CDER,
Office of Medical Products and Tobacco.
    Publication of this document constitutes final action on this
change under the Administrative Procedure Act (5 U.S.C. 553). FDA has
determined that notice and public comment are unnecessary because this
amendment to the regulations provides only a technical change to update
the

organizational information for the Office of Regulatory Policy, CDER,
Office of Medical Products and Tobacco.

List of Subjects in 21 CFR Part 5

    Authority delegations (Government agencies), Imports, Organization
and functions (Government agencies).

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, 21 CFR part
5 is amended as follows:

PART 5--ORGANIZATION

0
1. The authority citation for part 5 continues to read as follows:

    Authority:  5 U.S.C. 552; 21 U.S.C. 301-397.

Sec.  5.1100   [Amended]

0
2. In Sec.  5.1100, under the heading ``OFFICE OF MEDICAL PRODUCTS AND
TOBACCO'', under ``Office of Regulatory Policy.'', under ``Division of
Regulatory Policy III.'', add the words ``Division of Regulatory Policy
IV.''.

    Dated: March 21, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-06065 Filed 3-26-18; 8:45 am]
 BILLING CODE 4164-01-P